Mucosal expression of matrix metalloproteinases and their tissue inhibitors in ulcerative colitis patients

Journal of Gastroenterology

Volumn 38, Issue 4, 2003, Pages 412-413

  Kusugami, Kazuo ^a   Nobata, Kazuo ^a   Tsuzuki, Tomoyuki ^a   Ando, Takafumi ^a   Ina, Kenji ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

COLON CANCER; COLON MUCOSA; CORRELATION ANALYSIS; CROHN DISEASE; DEGRADATION; DYSPLASIA; EDITORIAL; ENTERITIS; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE INJURY; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0038189930     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350300075     Document Type: Editorial

References (18)

1. Kovacs EJ, DiPietro LA. Fibrogenic cytokines and connective tissue production. FASEB J 1994;11:854-61.
2. Basson MD. In vitro evidence for matrix regulation of intestinal epithelial biology during mucosal healing. Life Sci 2001;69:3005-18.
3. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
4. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, Airola K, Parks WC, Karjalainen-Lindsberg ML. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996;148:519-26.
5. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117:814-22.
6. Heuschkel RB, MacDonald TT, Monteleone G, Bajaj-Elliott M, Smith JA, Pender SL. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000;47:57-62.
7. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000;47:63-73.
8. Stallmach A, Chan CC, Ecker KW, Feifel G, Herbst H, Schuppan D, et al. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 2000;47:415-22.
9. Louis E, Ribbens C, Godon A, Franchimont D, De Groote D, Hardy N, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000;120:241-6.
10. Arihiro S, Ohtani H, Hiwatashi N, Torii A, Sorsa T, Nagura H. Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology 2001;39:50-9.
11. Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 1999;878: 212-27.
12. Vaalamo M, Karjalaninen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulceration. Am J Pathol 1998;152:1005-14.
13. Borkakoti N. Matrix metalloproteases: variations on a theme. Prog Biophys Mol Biol 1998;70:73-94.
14. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
15. Matsuno K, Adachi Y, Yamamoto H, Goto A, Arimura Y, Endo T, et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol 2003;38:348-54.
16. Madlener M, Mauch C, Conca W, Brauchle M, Parks WC, Werner S. Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. Biochem J 1996;320:659-64.
17. Salmela MT, MacDonald TT, Black D, Irvine B, Zhuma T, Saarialho-Kere U, et al. Upregulation of matrix metallopro teinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation. Gut 2002;51:540-7.
18. Adachi Y, Yamamoto H, Itoh F, Arimura Y, Nishi M, Endo T, et al. Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int J Cancer 2001;95:290-4.